fluoxetine has been researched along with Congenital Myasthenia in 13 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "DOK7 congenital myasthenic syndrome (DOK7-CMS) generally presents early in life and is treated with salbutamol or ephedrine." | 5.48 | DOK7 myasthenic syndrome with subacute adult onset during pregnancy and partial response to fluoxetine. ( Basto, JP; Cruz, S; Peres, J; Salgado, V; Santos, L; Santos, M; Tavares, P; Valverde, AH, 2018) |
| "The slow-channel congenital myasthenic syndrome is an autosomal dominant neuromuscular disorder caused by mutations in different subunits of the acetylcholine receptor." | 1.72 | Treatment of slow-channel congenital myasthenic syndrome in a Thai family with fluoxetine. ( Dejthevaporn, C; Engel, AG; Pulkes, T; Rattanasiri, S; Wetchaphanphesat, S; Witoonpanich, R, 2022) |
| "Congenital myasthenic syndromes are rare hereditary disorders caused by mutations associated with proteins of the neuromuscular junction." | 1.62 | Rare slow channel congenital myasthenic syndromes without repetitive compound muscle action potential and dramatic response to low dose fluoxetine. ( Ceylaner, S; Deymeer, F; Durmus, H; Hashemolhosseini, S; Sticht, H, 2021) |
| "Treatment with fluoxetine resulted in remarkable improvement and regain of muscle power and independence from assisted ventilation." | 1.62 | A rare mutation in the COLQ gene causing congenital myasthenic syndrome with remarkable improvement to fluoxetine: A case report. ( Beeson, D; Chang, T; Cossins, J; Fernando, A; Gooneratne, IK; Gunaratne, K; Maxwell, S; Nandasiri, S; Vidanagamage, A, 2021) |
| "DOK7 congenital myasthenic syndrome (DOK7-CMS) generally presents early in life and is treated with salbutamol or ephedrine." | 1.48 | DOK7 myasthenic syndrome with subacute adult onset during pregnancy and partial response to fluoxetine. ( Basto, JP; Cruz, S; Peres, J; Salgado, V; Santos, L; Santos, M; Tavares, P; Valverde, AH, 2018) |
| "Fluoxetine is a selective serotonin reuptake inhibitor and long-lived open channel blocker of the acetylcholine receptor, often used in the treatment of slow-channel congenital myasthenic syndromes (CMS)." | 1.46 | Rapsyn congenital myasthenic syndrome worsened by fluoxetine. ( Benarroch, EE; Laughlin, RS; Litchy, WJ; Milone, M; Visser, AC, 2017) |
| "The slow-channel congenital myasthenic syndrome (SCS) is an inherited neurodegenerative disease that caused mutations in the acetylcholine receptor (AChR) affecting neuromuscular transmission." | 1.42 | Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome. ( Alicea-Vázquez, V; Báez-Pagán, CA; Gomez, CM; Grajales-Reyes, GE; Grajales-Reyes, JG; Lasalde-Dominicci, JA; Pytel, P; Robinson, K; Zhu, H, 2015) |
| "Fluoxetine is an open channel blocker of fetal muscle acetylcholine (ACh) receptor (AChR) and slow-channel mutant AChRs." | 1.40 | Fluoxetine prevents acetylcholine-induced excitotoxicity blocking human endplate acetylcholine receptor. ( Catalano, M; Deflorio, C; Fucile, S; Grassi, F; Limatola, C, 2014) |
| "Slow channel congenital myasthenic syndrome is a dominant disorder characterized by prolonged acetylcholine receptor ion-channel activation." | 1.39 | Slow channel congenital myasthenic syndrome responsive to a combination of fluoxetine and salbutamol. ( Beeson, D; Finlayson, S; Howard, R; Kullmann, DM; Palace, J; Spillane, J; Webster, R, 2013) |
| "Slow-channel congenital myasthenic syndrome (CMS) is a rare subtype of CMS caused by dominant "gain of function" mutations in the acetylcholine receptor." | 1.38 | A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome. ( Abicht, A; Argov, Z; Chaouch, A; Colomer, J; Dusl, M; Guergueltcheva, V; Lindberg, C; Lochmüller, H; Muelas, N; Müller, JS; Nascimento, A; Rakocević-Stojanović, V; Schara, U; Scola, RH; Vilchez, JJ; Werneck, LC, 2012) |
| "Fluoxetine therapy was started and gradually increased over 2 months." | 1.33 | Long-term improvement of slow-channel congenital myasthenic syndrome with fluoxetine. ( Abicht, A; Colomer, J; Gonzalez, V; Lochmüller, H; Müller, JS; Nascimento, A; Pons, M; Vernet, A, 2006) |
| "The slow-channel syndrome is one of the congenital myasthenic syndromes attributed to inherited kinetic disorders of the ion channel of the acetylcholine receptor of the neuromuscular junction." | 1.33 | [Neurophysiological study in slow-channel congenital myasthenic syndrome: case report]. ( Arruda, WO; Kay, CS; Lorenzoni, PJ; Scola, RH; Werneck, LC, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Dejthevaporn, C | 1 |
| Wetchaphanphesat, S | 1 |
| Pulkes, T | 1 |
| Rattanasiri, S | 1 |
| Engel, AG | 2 |
| Witoonpanich, R | 1 |
| Durmus, H | 1 |
| Sticht, H | 1 |
| Ceylaner, S | 1 |
| Hashemolhosseini, S | 1 |
| Deymeer, F | 1 |
| Vidanagamage, A | 1 |
| Gooneratne, IK | 1 |
| Nandasiri, S | 1 |
| Gunaratne, K | 1 |
| Fernando, A | 1 |
| Maxwell, S | 1 |
| Cossins, J | 1 |
| Beeson, D | 3 |
| Chang, T | 1 |
| Lee, M | 1 |
| Palace, J | 2 |
| Santos, M | 1 |
| Cruz, S | 1 |
| Peres, J | 1 |
| Santos, L | 1 |
| Tavares, P | 1 |
| Basto, JP | 1 |
| Salgado, V | 1 |
| Valverde, AH | 1 |
| Deflorio, C | 1 |
| Catalano, M | 1 |
| Fucile, S | 1 |
| Limatola, C | 1 |
| Grassi, F | 1 |
| Zhu, H | 1 |
| Grajales-Reyes, GE | 1 |
| Alicea-Vázquez, V | 1 |
| Grajales-Reyes, JG | 1 |
| Robinson, K | 1 |
| Pytel, P | 1 |
| Báez-Pagán, CA | 1 |
| Lasalde-Dominicci, JA | 1 |
| Gomez, CM | 1 |
| Visser, AC | 1 |
| Laughlin, RS | 1 |
| Litchy, WJ | 1 |
| Benarroch, EE | 1 |
| Milone, M | 1 |
| Chaouch, A | 1 |
| Müller, JS | 2 |
| Guergueltcheva, V | 1 |
| Dusl, M | 1 |
| Schara, U | 1 |
| Rakocević-Stojanović, V | 1 |
| Lindberg, C | 1 |
| Scola, RH | 2 |
| Werneck, LC | 2 |
| Colomer, J | 2 |
| Nascimento, A | 2 |
| Vilchez, JJ | 1 |
| Muelas, N | 1 |
| Argov, Z | 1 |
| Abicht, A | 2 |
| Lochmüller, H | 2 |
| Finlayson, S | 1 |
| Spillane, J | 1 |
| Kullmann, DM | 1 |
| Howard, R | 1 |
| Webster, R | 1 |
| Harper, CM | 1 |
| Fukodome, T | 1 |
| Vernet, A | 1 |
| Pons, M | 1 |
| Gonzalez, V | 1 |
| Lorenzoni, PJ | 1 |
| Kay, CS | 1 |
| Arruda, WO | 1 |
1 review available for fluoxetine and Congenital Myasthenia
| Article | Year |
|---|---|
Therapeutic strategies for congenital myasthenic syndromes.
Topics: Adrenergic beta-Agonists; Breast Feeding; Cholinergic Antagonists; Cholinesterase Inhibitors; Female | 2018 |
12 other studies available for fluoxetine and Congenital Myasthenia
| Article | Year |
|---|---|
Treatment of slow-channel congenital myasthenic syndrome in a Thai family with fluoxetine.
Topics: Fluoxetine; Humans; Mutation; Myasthenic Syndromes, Congenital; Prospective Studies; Receptors, Chol | 2022 |
Rare slow channel congenital myasthenic syndromes without repetitive compound muscle action potential and dramatic response to low dose fluoxetine.
Topics: Action Potentials; Adult; Amino Acid Sequence; Dose-Response Relationship, Drug; Fluoxetine; Humans; | 2021 |
A rare mutation in the COLQ gene causing congenital myasthenic syndrome with remarkable improvement to fluoxetine: A case report.
Topics: Acetylcholinesterase; Asian People; Collagen; Fluoxetine; Humans; Male; Middle Aged; Muscle Proteins | 2021 |
DOK7 myasthenic syndrome with subacute adult onset during pregnancy and partial response to fluoxetine.
Topics: Adult; Female; Fluoxetine; Humans; Muscle Proteins; Muscle Weakness; Myasthenic Syndromes, Congenita | 2018 |
Fluoxetine prevents acetylcholine-induced excitotoxicity blocking human endplate acetylcholine receptor.
Topics: Acetylcholine; Cell Death; Cell Survival; Cells, Cultured; Fluoxetine; HEK293 Cells; Humans; In Vitr | 2014 |
Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome.
Topics: Animals; Disease Models, Animal; Fluoxetine; Male; Mice; Mice, Transgenic; Motor Activity; Myastheni | 2015 |
Rapsyn congenital myasthenic syndrome worsened by fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Female; Fluoxetine; Humans; Muscle Proteins; Mutati | 2017 |
A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome.
Topics: Adolescent; Adult; Aged; Cholinesterase Inhibitors; Female; Fluoxetine; Follow-Up Studies; Humans; M | 2012 |
Slow channel congenital myasthenic syndrome responsive to a combination of fluoxetine and salbutamol.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Drug Therapy, Combination; Fluoxetine; Humans; Male; | 2013 |
Treatment of slow-channel congenital myasthenic syndrome with fluoxetine.
Topics: Adult; Cholinergic Antagonists; Drug Evaluation; Drug Hypersensitivity; Female; Fluoxetine; Genes, D | 2003 |
Long-term improvement of slow-channel congenital myasthenic syndrome with fluoxetine.
Topics: Adolescent; Cholinesterase Inhibitors; DNA Mutational Analysis; Dose-Response Relationship, Drug; Dr | 2006 |
[Neurophysiological study in slow-channel congenital myasthenic syndrome: case report].
Topics: Action Potentials; Adult; Electric Stimulation; Electromyography; Electrophysiology; Fluoxetine; Hum | 2006 |